Standard BioTools posts Q1 2026 revenue growth and narrows losses, aiming for profitability this year

Standard BioTools Inc. reported a 5% revenue increase to $21.1 million in Q1 2026, driven by strong consumables sales despite a 33% drop in instrument revenue. The company reduced its operating loss by 54% and improved adjusted EBITDA loss by 78%, signaling progress toward profitability in 2026. With $524 million in cash and investments, Standard BioTools plans to pursue growth opportunities following the sale of SomaLogic. The company maintains its 2026 revenue forecast of $80-$85 million, focusing on cost savings and strategic capital deployment.